The new drug Litfulo (ritlecitinib) has reached the Canadian market, while baricitinib (Olumiant) is now approved for alopecia areata and in a new higher-strength tablet.
Provincial Health Minister Adrian Dix says the nursing ratios will be a first for Canada, and no other jurisdiction in the world has a minimum ratio that applies at all times.